1-1	0-12	Disturbances	_	_
1-2	13-19	across	_	_
1-3	20-25	whole	_	_
1-4	26-31	brain	_	_
1-5	32-40	networks	_	_
1-6	41-47	during	_	_
1-7	48-54	reward	_	_
1-8	55-67	anticipation	_	_
1-9	68-70	in	_	_
1-10	71-73	an	_	_
1-11	74-83	abstinent	_	_
1-12	84-93	addiction	_	_
1-13	94-104	population	_	_
1-14	105-114	Graphical	_	_
1-15	115-123	abstract	_	_
1-16	124-131	Network	_	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-17	132-137	based	_	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-18	138-148	statistics	_	_
1-19	149-150	(	_	_
1-20	150-153	NBS	_	_
1-21	153-154	)	_	_
1-22	155-163	analyses	_	_
1-23	164-172	detected	_	_
1-24	173-174	a	_	_
1-25	175-180	graph	_	_
1-26	181-192	sub-network	_	_
1-27	193-203	comprising	_	_
1-28	204-207	153	_	_
1-29	208-213	edges	_	_
1-30	214-221	between	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-31	222-224	59	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	225-230	nodes	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-33	231-233	of	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-34	234-237	the	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-35	238-248	connectome	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-36	249-254	where	_	_
1-37	255-258	the	_	_
1-38	259-262	ADD	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
1-39	263-268	group	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
1-40	269-281	demonstrated	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-41	282-295	significantly	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-42	296-300	less	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-43	301-313	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
1-44	314-322	compared	_	_
1-45	323-327	with	_	_
1-46	328-331	the	_	_
1-47	332-335	CON	_	_
1-48	336-341	group	_	_
1-49	341-342	.	_	_

2-1	343-348	These	_	_
2-2	349-360	differences	_	_
2-3	361-363	in	_	_
2-4	364-376	connectivity	_	_
2-5	377-381	were	_	_
2-6	382-388	mostly	_	_
2-7	389-406	intra-hemispheric	_	_
2-8	407-408	(	_	_
2-9	408-411	55%	_	_
2-10	411-412	)	_	_
2-11	412-413	,	_	_
2-12	414-417	the	_	_
2-13	418-426	majority	_	_
2-14	427-428	(	_	_
2-15	428-431	38%	_	_
2-16	431-432	)	_	_
2-17	433-438	being	_	_
2-18	439-441	in	_	_
2-19	442-445	the	_	_
2-20	446-451	right	_	_
2-21	452-462	hemisphere	_	_
2-22	462-463	.	_	_

3-1	464-467	The	_	_
3-2	468-478	anatomical	_	_
3-3	479-491	distribution	_	_
3-4	492-494	of	_	_
3-5	495-500	these	_	_
3-6	501-513	connectivity	_	_
3-7	514-525	differences	_	_
3-8	526-533	between	_	_
3-9	534-537	the	_	_
3-10	538-541	two	_	_
3-11	542-548	groups	_	_
3-12	549-557	involved	_	_
3-13	558-565	frontal	_	_
3-14	566-567	(	_	_
3-15	567-573	insula	_	_
3-16	573-574	,	_	_
3-17	575-583	inferior	_	_
3-18	584-591	frontal	_	_
3-19	592-597	gyrus	_	_
3-20	597-598	,	_	_
3-21	599-612	orbitofrontal	_	_
3-22	613-619	cortex	_	_
3-23	619-620	)	_	_
3-24	620-621	,	_	_
3-25	622-639	limbic-associated	_	_
3-26	640-641	(	_	_
3-27	641-649	anterior	_	_
3-28	650-659	cingulate	_	_
3-29	660-665	gyrus	_	_
3-30	665-666	,	_	_
3-31	667-675	thalamus	_	_
3-32	675-676	)	_	_
3-33	676-677	,	_	_
3-34	678-681	and	_	_
3-35	682-690	striatal	_	_
3-36	691-692	(	_	_
3-37	692-701	accumbens	_	_
3-38	701-702	,	_	_
3-39	703-710	caudate	_	_
3-40	710-711	,	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
3-41	712-720	pallidum	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
3-42	720-721	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-43	722-729	regions	_	_
3-44	729-730	.	_	_

4-1	731-734	The	_	_
4-2	735-747	connectivity	_	_
4-3	748-759	differences	_	_
4-4	760-768	reported	_	_
4-5	769-771	in	_	_
4-6	772-776	this	_	_
4-7	777-780	ADD	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-8	781-787	sample	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-9	788-796	indicate	_	_
4-10	797-808	alterations	_	_
4-11	809-816	between	_	_
4-12	817-826	cognitive	_	_
4-13	826-827	,	_	_
4-14	828-836	striatal	_	_
4-15	837-840	and	_	_
4-16	841-858	limbic-associated	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-17	859-866	regions	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-18	867-873	during	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-19	874-880	reward	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-20	881-893	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-21	894-898	that	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-22	899-906	persist	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-23	907-911	into	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-24	912-920	extended	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-25	921-931	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
4-26	931-932	.	_	_

5-1	933-943	Highlights	_	_
5-2	944-954	Analytical	_	_
5-3	955-962	methods	_	_
5-4	963-966	can	_	_
5-5	967-974	capture	_	_
5-6	975-978	key	_	_
5-7	979-987	features	_	_
5-8	988-990	of	_	_
5-9	991-996	whole	_	_
5-10	997-1002	brain	_	_
5-11	1003-1011	networks	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
5-12	1012-1014	in	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
5-13	1015-1024	addiction	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
5-14	1024-1025	.	_	_

6-1	1026-1028	We	_	_
6-2	1029-1037	compared	_	_
6-3	1038-1044	reward	_	_
6-4	1045-1052	network	_	_
6-5	1053-1065	connectivity	_	_
6-6	1066-1068	in	_	_
6-7	1069-1078	addiction	_	_
6-8	1079-1080	(	_	_
6-9	1080-1083	ADD	_	_
6-10	1083-1084	)	_	_
6-11	1085-1088	and	_	_
6-12	1089-1096	control	_	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
6-13	1097-1098	(	_	_
6-14	1098-1101	CON	_	_
6-15	1101-1102	)	_	_
6-16	1103-1109	groups	_	_
6-17	1109-1110	.	_	_

7-1	1111-1114	The	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
7-2	1115-1118	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
7-3	1119-1124	group	_	_
7-4	1125-1131	showed	_	_
7-5	1132-1143	disruptions	_	_
7-6	1144-1146	in	_	_
7-7	1147-1153	global	_	_
7-8	1154-1161	network	_	_
7-9	1162-1174	connectivity	_	_
7-10	1174-1175	.	_	_

8-1	1176-1182	Global	_	_
8-2	1183-1190	network	_	_
8-3	1191-1199	measures	_	_
8-4	1200-1203	may	_	_
8-5	1204-1206	be	_	_
8-6	1207-1211	more	_	_
8-7	1212-1221	sensitive	_	_
8-8	1222-1226	than	_	_
8-9	1227-1238	traditional	_	_
8-10	1239-1249	voxel-wise	_	_
8-11	1250-1258	analyses	_	_
8-12	1258-1259	.	_	_

9-1	1260-1263	The	_	_
9-2	1264-1273	prevalent	_	_
9-3	1274-1281	spatial	_	_
9-4	1282-1294	distribution	_	_
9-5	1295-1297	of	_	_
9-6	1298-1311	abnormalities	_	_
9-7	1312-1320	reported	_	_
9-8	1321-1323	in	_	_
9-9	1324-1333	cognitive	_	_
9-10	1334-1338	fMRI	_	_
9-11	1339-1346	studies	_	_
9-12	1347-1349	in	_	_
9-13	1350-1359	addiction	_	_
9-14	1360-1368	suggests	_	_
9-15	1369-1374	there	_	_
9-16	1375-1378	are	_	_
9-17	1379-1388	extensive	_	_
9-18	1389-1400	disruptions	_	_
9-19	1401-1407	across	_	_
9-20	1408-1413	whole	_	_
9-21	1414-1419	brain	_	_
9-22	1420-1428	networks	_	_
9-23	1428-1429	.	_	_

10-1	1430-1437	Studies	_	_
10-2	1438-1443	using	_	_
10-3	1444-1451	resting	_	_
10-4	1452-1457	state	_	_
10-5	1458-1462	have	_	_
10-6	1463-1471	reported	_	_
10-7	1472-1483	disruptions	_	_
10-8	1484-1486	in	_	_
10-9	1487-1494	network	_	_
10-10	1495-1507	connectivity	_	_
10-11	1508-1510	in	_	_
10-12	1511-1520	addiction	_	_
10-13	1520-1521	,	_	_
10-14	1522-1525	but	_	_
10-15	1526-1531	these	_	_
10-16	1532-1539	studies	_	_
10-17	1540-1544	have	_	_
10-18	1545-1548	not	_	_
10-19	1549-1557	revealed	_	_
10-20	1558-1573	characteristics	_	_
10-21	1574-1576	of	_	_
10-22	1577-1584	network	_	_
10-23	1585-1596	functioning	_	_
10-24	1597-1603	during	_	_
10-25	1604-1612	critical	_	_
10-26	1613-1626	psychological	_	_
10-27	1627-1636	processes	_	_
10-28	1637-1641	that	_	_
10-29	1642-1645	are	_	_
10-30	1646-1655	disrupted	_	_
10-31	1656-1658	in	_	_
10-32	1659-1668	addiction	_	_
10-33	1669-1680	populations	_	_
10-34	1680-1681	.	_	_

11-1	1682-1690	Analytic	_	_
11-2	1691-1698	methods	_	_
11-3	1699-1703	that	_	_
11-4	1704-1707	can	_	_
11-5	1708-1715	capture	_	_
11-6	1716-1719	key	_	_
11-7	1720-1728	features	_	_
11-8	1729-1731	of	_	_
11-9	1732-1737	whole	_	_
11-10	1738-1743	brain	_	_
11-11	1744-1752	networks	_	_
11-12	1753-1759	during	_	_
11-13	1760-1773	psychological	_	_
11-14	1774-1783	processes	_	_
11-15	1784-1787	may	_	_
11-16	1788-1790	be	_	_
11-17	1791-1795	more	_	_
11-18	1796-1805	sensitive	_	_
11-19	1806-1808	in	_	_
11-20	1809-1818	revealing	_	_
11-21	1819-1829	additional	_	_
11-22	1830-1833	and	_	_
11-23	1834-1844	widespread	_	_
11-24	1845-1851	neural	_	_
11-25	1852-1864	disturbances	_	_
11-26	1865-1867	in	_	_
11-27	1868-1877	addiction	_	_
11-28	1877-1878	,	_	_
11-29	1879-1883	that	_	_
11-30	1884-1887	are	_	_
11-31	1888-1891	the	_	_
11-32	1892-1902	provisions	_	_
11-33	1903-1906	for	_	_
11-34	1907-1914	relapse	_	_
11-35	1915-1919	risk	_	_
11-36	1919-1920	,	_	_
11-37	1921-1924	and	_	_
11-38	1925-1932	targets	_	_
11-39	1933-1936	for	_	_
11-40	1937-1947	medication	_	_
11-41	1948-1959	development	_	_
11-42	1959-1960	.	_	_

12-1	1961-1964	The	_	_
12-2	1965-1972	current	_	_
12-3	1973-1978	study	_	_
12-4	1979-1987	compared	_	_
12-5	1988-1989	a	_	_
12-6	1990-1999	substance	_	_
12-7	2000-2009	addiction	_	_
12-8	2010-2011	(	_	_
12-9	2011-2014	ADD	_	_
12-10	2014-2015	;	_	_
12-11	2016-2017	n	_	_
12-12	2017-2018	 	_	_
12-13	2018-2019	=	_	_
12-14	2019-2020	 	_	_
12-15	2020-2022	83	_	_
12-16	2022-2023	)	_	_
12-17	2024-2029	group	_	_
12-18	2030-2032	in	_	_
12-19	2033-2041	extended	_	_
12-20	2042-2052	abstinence	_	_
12-21	2053-2057	with	_	_
12-22	2058-2059	a	_	_
12-23	2060-2067	control	_	_
12-24	2068-2069	(	_	_
12-25	2069-2072	CON	_	_
12-26	2072-2073	;	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-27	2074-2075	n	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-28	2075-2076	 	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-29	2076-2077	=	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-30	2077-2078	 	_	_
12-31	2078-2080	68	_	_
12-32	2080-2081	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
12-33	2082-2087	group	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
12-34	2088-2090	on	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-35	2091-2101	functional	_	_
12-36	2102-2105	MRI	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
12-37	2106-2107	(	_	_
12-38	2107-2117	voxel-wise	_	_
12-39	2118-2128	activation	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-40	2128-2129	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-41	2130-2133	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-42	2134-2140	global	_	_
12-43	2141-2148	network	_	_
12-44	2149-2150	(	_	_
12-45	2150-2162	connectivity	_	_
12-46	2162-2163	)	_	_
12-47	2164-2172	measures	_	_
12-48	2173-2180	related	_	_
12-49	2181-2183	to	_	_
12-50	2184-2190	reward	_	_
12-51	2191-2203	anticipation	_	_
12-52	2204-2206	on	_	_
12-53	2207-2208	a	_	_
12-54	2209-2217	monetary	_	_
12-55	2218-2227	incentive	_	_
12-56	2228-2233	delay	_	_
12-57	2234-2238	task	_	_
12-58	2238-2239	.	_	_

13-1	2240-2242	In	_	_
13-2	2243-2246	the	_	_
13-3	2247-2254	absence	_	_
13-4	2255-2257	of	_	_
13-5	2258-2263	group	_	_
13-6	2264-2275	differences	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
13-7	2276-2278	on	_	_
13-8	2279-2282	MID	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-9	2283-2294	performance	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-10	2294-2295	,	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-11	2296-2299	the	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-12	2300-2303	ADD	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-13	2304-2309	group	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-14	2310-2316	showed	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-15	2317-2324	reduced	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-16	2325-2335	activation	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-17	2336-2349	predominantly	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-18	2350-2356	across	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-19	2357-2365	temporal	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-20	2366-2369	and	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-21	2370-2376	visual	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-22	2377-2384	regions	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-23	2384-2385	,	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-24	2386-2389	but	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-25	2390-2393	not	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-26	2394-2400	across	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-27	2401-2404	the	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse	_
13-28	2405-2413	striatum	_	_
13-29	2413-2414	.	_	_

14-1	2415-2418	The	_	_
14-2	2419-2422	ADD	_	_
14-3	2423-2428	group	_	_
14-4	2429-2433	also	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
14-5	2434-2440	showed	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
14-6	2441-2452	disruptions	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
14-7	2453-2455	in	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
14-8	2456-2462	global	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
14-9	2463-2470	network	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
14-10	2471-2483	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
14-11	2484-2485	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	_
14-12	2485-2490	lower	_	_
14-13	2491-2501	clustering	_	_
14-14	2502-2513	coefficient	_	_
14-15	2514-2517	and	_	_
14-16	2518-2524	higher	_	_
14-17	2525-2539	characteristic	_	_
14-18	2540-2544	path	_	_
14-19	2545-2551	length	_	_
14-20	2551-2552	)	_	_
14-21	2552-2553	,	_	_
14-22	2554-2557	and	_	_
14-23	2558-2571	significantly	_	_
14-24	2572-2576	less	_	_
14-25	2577-2589	connectivity	_	_
14-26	2590-2596	across	_	_
14-27	2597-2598	a	_	_
14-28	2599-2610	sub-network	_	_
14-29	2611-2621	comprising	_	_
14-30	2622-2629	frontal	_	_
14-31	2629-2630	,	_	_
14-32	2631-2639	temporal	_	_
14-33	2639-2640	,	_	_
14-34	2641-2647	limbic	_	_
14-35	2648-2651	and	_	_
14-36	2652-2660	striatal	_	_
14-37	2661-2666	nodes	_	_
14-38	2666-2667	.	_	_

15-1	2668-2673	These	_	_
15-2	2674-2681	results	_	_
15-3	2682-2686	show	_	_
15-4	2687-2691	that	_	_
15-5	2692-2694	an	_	_
15-6	2695-2704	addiction	_	_
15-7	2705-2710	group	_	_
15-8	2711-2713	in	_	_
15-9	2714-2722	extended	_	_
15-10	2723-2733	abstinence	_	_
15-11	2734-2741	exhibit	_	_
15-12	2742-2751	localised	_	_
15-13	2752-2763	disruptions	_	_
15-14	2764-2766	in	_	_
15-15	2767-2772	brain	_	_
15-16	2773-2783	activation	_	_
15-17	2783-2784	,	_	_
15-18	2785-2788	but	_	_
15-19	2789-2793	more	_	_
15-20	2794-2803	extensive	_	_
15-21	2804-2816	disturbances	_	_
15-22	2817-2819	in	_	_
15-23	2820-2830	functional	_	_
15-24	2831-2843	connectivity	_	_
15-25	2844-2850	across	_	_
15-26	2851-2856	whole	_	_
15-27	2857-2862	brain	_	_
15-28	2863-2871	networks	_	_
15-29	2871-2872	.	_	_

16-1	2873-2875	We	_	_
16-2	2876-2883	propose	_	_
16-3	2884-2888	that	_	_
16-4	2889-2897	measures	_	_
16-5	2898-2900	of	_	_
16-6	2901-2907	global	_	_
16-7	2908-2915	network	_	_
16-8	2916-2927	functioning	_	_
16-9	2928-2931	may	_	_
16-10	2932-2934	be	_	_
16-11	2935-2939	more	_	_
16-12	2940-2949	sensitive	_	_
16-13	2950-2952	in	_	_
16-14	2953-2965	highlighting	_	_
16-15	2966-2972	latent	_	_
16-16	2973-2976	and	_	_
16-17	2977-2981	more	_	_
16-18	2982-2992	widespread	_	_
16-19	2993-2999	neural	_	_
16-20	3000-3011	disruptions	_	_
16-21	3012-3018	during	_	_
16-22	3019-3027	critical	_	_
16-23	3028-3041	psychological	_	_
16-24	3042-3051	processes	_	_
16-25	3052-3054	in	_	_
16-26	3055-3064	addiction	_	_
16-27	3065-3068	and	_	_
16-28	3069-3074	other	_	_
16-29	3075-3086	psychiatric	_	_
16-30	3087-3096	disorders	_	_
16-31	3096-3097	.	_	_

31-1	6090-6098	Material	_	_
31-2	6099-6102	and	_	_
31-3	6103-6110	methods	_	_
31-4	6111-6123	Participants	_	_
31-5	6124-6135	Sixty-eight	_	_
31-6	6136-6143	control	_	_
31-7	6144-6145	(	_	_
31-8	6145-6148	CON	_	_
31-9	6148-6149	:	_	_
31-10	6150-6154	mean	_	_
31-11	6155-6158	age	_	_
31-12	6159-6164	39.79	_	_
31-13	6164-6165	 	_	_
31-14	6165-6166	±	_	_
31-15	6166-6167	 	_	_
31-16	6167-6171	1.22	_	_
31-17	6171-6172	;	_	_
31-18	6173-6175	18	_	_
31-19	6176-6183	females	_	_
31-20	6183-6184	,	_	_
31-21	6185-6187	50	_	_
31-22	6188-6193	males	_	_
31-23	6193-6194	)	_	_
31-24	6195-6198	and	_	_
31-25	6199-6201	83	_	_
31-26	6202-6211	addiction	_	_
31-27	6212-6213	(	_	_
31-28	6213-6216	ADD	_	_
31-29	6216-6217	:	_	_
31-30	6218-6222	mean	_	_
31-31	6223-6226	age	_	_
31-32	6227-6232	40.05	_	_
31-33	6232-6233	 	_	_
31-34	6233-6234	±	_	_
31-35	6234-6235	 	_	_
31-36	6235-6239	0.92	_	_
31-37	6239-6240	;	_	_
31-38	6241-6243	16	_	_
31-39	6244-6251	females	_	_
31-40	6251-6252	,	_	_
31-41	6253-6255	67	_	_
31-42	6256-6261	males	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
31-43	6261-6262	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
31-44	6263-6275	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
31-45	6276-6285	completed	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
31-46	6286-6289	the	_	_
31-47	6290-6297	current	_	_
31-48	6298-6303	study	_	_
31-49	6303-6304	.	_	_

32-1	6305-6308	The	_	_
32-2	6309-6316	current	_	_
32-3	6317-6324	dataset	_	_
32-4	6325-6328	was	_	_
32-5	6329-6338	collected	_	_
32-6	6339-6341	as	_	_
32-7	6342-6346	part	_	_
32-8	6347-6349	of	_	_
32-9	6350-6351	a	_	_
32-10	6352-6364	multi-centre	_	_
32-11	6365-6370	study	_	_
32-12	6371-6380	involving	_	_
32-13	6381-6386	three	_	_
32-14	6387-6392	study	_	_
32-15	6393-6398	sites	_	_
32-16	6399-6401	in	_	_
32-17	6402-6405	the	_	_
32-18	6406-6412	United	_	_
32-19	6413-6420	Kingdom	_	_
32-20	6421-6422	(	_	_
32-21	6422-6430	Imperial	_	_
32-22	6431-6438	College	_	_
32-23	6439-6445	London	_	_
32-24	6445-6446	,	_	_
32-25	6447-6457	University	_	_
32-26	6458-6460	of	_	_
32-27	6461-6470	Cambridge	_	_
32-28	6471-6474	and	_	_
32-29	6475-6485	University	_	_
32-30	6486-6488	of	_	_
32-31	6489-6499	Manchester	_	_
32-32	6500-6501	–	_	_
32-33	6502-6507	ICCAM	_	_
32-34	6507-6508	)	_	_
32-35	6508-6509	.	_	_

33-1	6510-6513	For	_	_
33-2	6514-6515	a	_	_
33-3	6516-6520	more	_	_
33-4	6521-6529	detailed	_	_
33-5	6530-6541	description	_	_
33-6	6542-6544	of	_	_
33-7	6545-6548	the	_	_
33-8	6549-6554	ICCAM	_	_
33-9	6555-6563	Platform	_	_
33-10	6563-6564	,	_	_
33-11	6565-6568	see	_	_
33-12	6568-6569	)	_	_
33-13	6570-6573	and	_	_
33-14	6573-6574	.	_	_

34-1	6575-6584	Inclusion	_	_
34-2	6585-6593	criteria	_	_
34-3	6594-6598	were	_	_
34-4	6599-6610	individuals	_	_
34-5	6611-6614	who	_	_
34-6	6615-6618	met	_	_
34-7	6619-6625	DSM-IV	_	_
34-8	6626-6634	measures	_	_
34-9	6635-6638	for	_	_
34-10	6639-6646	current	_	_
34-11	6647-6649	or	_	_
34-12	6650-6655	prior	_	_
34-13	6656-6665	substance	_	_
34-14	6666-6676	dependence	_	_
34-15	6677-6678	(	_	_
34-16	6678-6681	e.g	_	_
34-17	6681-6682	.	_	_
34-18	6682-6683	,	_	_
34-19	6684-6691	alcohol	_	_
34-20	6691-6692	,	_	_
34-21	6693-6700	cocaine	_	_
34-22	6700-6701	,	_	_
34-23	6702-6709	opiates	_	_
34-24	6709-6710	)	_	_
34-25	6710-6711	.	_	_

35-1	6712-6715	The	_	_
35-2	6716-6719	ADD	_	_
35-3	6720-6725	group	_	_
35-4	6726-6735	consisted	_	_
35-5	6736-6738	of	_	_
35-6	6739-6741	29	_	_
35-7	6742-6743	(	_	_
35-8	6743-6746	35%	_	_
35-9	6746-6747	)	_	_
35-10	6748-6752	pure	_	_
35-11	6753-6770	alcohol-dependent	_	_
35-12	6770-6771	,	_	_
35-13	6772-6774	42	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	_
35-14	6775-6776	(	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	_
35-15	6776-6779	50%	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#SleepAndHealthModifiedScoreQuestionnaire
35-16	6779-6780	)	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	_
35-17	6781-6785	poly	_	_
35-18	6786-6805	substance-dependent	_	_
35-19	6806-6807	(	_	_
35-20	6807-6810	e.g	_	_
35-21	6810-6811	.	_	_
35-22	6811-6812	,	_	_
35-23	6813-6820	alcohol	_	_
35-24	6821-6824	and	_	_
35-25	6825-6832	cocaine	_	_
35-26	6832-6833	,	_	_
35-27	6834-6841	cocaine	_	_
35-28	6842-6845	and	_	_
35-29	6846-6852	opiate	_	_
35-30	6852-6853	)	_	_
35-31	6854-6857	and	_	_
35-32	6858-6860	12	_	_
35-33	6861-6862	(	_	_
35-34	6862-6865	15%	_	_
35-35	6865-6866	)	_	_
35-36	6867-6871	mono	_	_
35-37	6872-6891	substance-dependent	_	_
35-38	6892-6893	(	_	_
35-39	6893-6896	e.g	_	_
35-40	6896-6897	.	_	_
35-41	6897-6898	,	_	_
35-42	6899-6906	cocaine	_	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingSession
35-43	6906-6907	,	_	_
35-44	6908-6915	opiates	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-45	6915-6916	)	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-46	6917-6927	volunteers	_	_
35-47	6927-6928	.	_	_

36-1	6929-6934	While	_	_
36-2	6935-6944	addiction	_	_
36-3	6945-6952	studies	_	_
36-4	6953-6962	typically	_	_
36-5	6963-6970	recruit	_	_
36-6	6971-6981	volunteers	_	_
36-7	6982-6984	in	_	_
36-8	6985-6990	early	_	_
36-9	6991-7001	abstinence	_	_
36-10	7001-7002	,	_	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingSession
36-11	7003-7008	there	_	_
36-12	7009-7012	was	_	_
36-13	7013-7015	no	_	_
36-14	7016-7021	upper	_	_
36-15	7022-7027	limit	_	_
36-16	7028-7030	in	_	_
36-17	7031-7034	the	_	_
36-18	7035-7042	current	_	_
36-19	7043-7048	study	_	_
36-20	7048-7049	.	_	_

37-1	7050-7053	The	_	_
37-2	7054-7058	mean	_	_
37-3	7059-7069	abstinence	_	_
37-4	7070-7076	length	_	_
37-5	7077-7081	from	_	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
37-6	7082-7089	alcohol	_	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
37-7	7090-7092	in	_	_
37-8	7093-7096	the	_	_
37-9	7097-7104	current	_	_
37-10	7105-7111	sample	_	_
37-11	7112-7115	was	_	_
37-12	7116-7121	15.00	_	_
37-13	7121-7122	 	_	_
37-14	7122-7123	±	_	_
37-15	7123-7124	 	_	_
37-16	7124-7128	3.50	_	_
37-17	7128-7129	 	_	_
37-18	7129-7135	months	_	_
37-19	7135-7136	,	_	_
37-20	7137-7142	while	_	_
37-21	7143-7146	for	_	_
37-22	7147-7154	cocaine	_	_
37-23	7155-7158	and	_	_
37-24	7159-7166	opiates	_	_
37-25	7167-7169	it	_	_
37-26	7170-7173	was	_	_
37-27	7174-7179	27.99	_	_
37-28	7179-7180	 	_	_
37-29	7180-7181	±	_	_
37-30	7181-7182	 	_	_
37-31	7182-7186	3.72	_	_
37-32	7187-7190	and	_	_
37-33	7191-7196	39.04	_	_
37-34	7196-7197	 	_	_
37-35	7197-7198	±	_	_
37-36	7198-7199	 	_	_
37-37	7199-7203	7.75	_	_
37-38	7203-7204	 	_	_
37-39	7204-7210	months	_	_
37-40	7210-7211	,	_	_
37-41	7212-7224	respectively	_	_
37-42	7224-7225	.	_	_

38-1	7226-7235	Therefore	_	_
38-2	7235-7236	,	_	_
38-3	7237-7240	the	_	_
38-4	7241-7248	current	_	_
38-5	7249-7252	ADD	_	_
38-6	7253-7258	group	_	_
38-7	7259-7262	was	_	_
38-8	7263-7267	made	_	_
38-9	7268-7270	of	_	_
38-10	7271-7272	a	_	_
38-11	7273-7285	heterogenous	_	_
38-12	7286-7292	sample	_	_
38-13	7293-7297	with	_	_
38-14	7298-7304	former	_	_
38-15	7305-7327	substance-dependencies	_	_
38-16	7327-7328	,	_	_
38-17	7329-7332	and	_	_
38-18	7333-7337	with	_	_
38-19	7338-7346	variable	_	_
38-20	7347-7353	levels	_	_
38-21	7354-7356	of	_	_
38-22	7357-7366	substance	_	_
38-23	7367-7377	abstinence	_	_
38-24	7378-7380	at	_	_
38-25	7381-7384	the	_	_
38-26	7385-7389	time	_	_
38-27	7390-7392	of	_	_
38-28	7393-7400	testing	_	_
38-29	7400-7401	.	_	_

39-1	7402-7406	This	_	_
39-2	7407-7412	meant	_	_
39-3	7413-7417	that	_	_
39-4	7418-7423	there	_	_
39-5	7424-7427	was	_	_
39-6	7428-7430	no	_	_
39-7	7431-7440	substance	_	_
39-8	7441-7451	dependence	_	_
39-9	7452-7459	measure	_	_
39-10	7460-7464	that	_	_
39-11	7465-7468	was	_	_
39-12	7469-7475	shared	_	_
39-13	7476-7478	by	_	_
39-14	7479-7482	all	_	_
39-15	7483-7490	members	_	_
39-16	7491-7493	of	_	_
39-17	7494-7497	the	_	_
39-18	7498-7501	ADD	_	_
39-19	7502-7507	group	_	_
39-20	7507-7508	.	_	_

40-1	7509-7512	The	_	_
40-2	7513-7516	CON	_	_
40-3	7517-7522	group	_	_
40-4	7523-7526	had	_	_
40-5	7527-7529	no	_	_
40-6	7530-7538	previous	_	_
40-7	7539-7546	history	_	_
40-8	7547-7549	of	_	_
40-9	7550-7559	substance	_	_
40-10	7560-7565	abuse	_	_
40-11	7565-7566	,	_	_
40-12	7567-7569	as	_	_
40-13	7570-7578	assessed	_	_
40-14	7579-7584	using	_	_
40-15	7585-7588	the	_	_
40-16	7589-7596	Alcohol	_	_
40-17	7596-7597	,	_	_
40-18	7598-7605	Smoking	_	_
40-19	7606-7609	and	_	_
40-20	7610-7619	Substance	_	_
40-21	7620-7631	Involvement	_	_
40-22	7632-7641	Screening	_	_
40-23	7642-7646	Test	_	_
40-24	7647-7648	(	_	_
40-25	7648-7654	ASSIST	_	_
40-26	7654-7655	)	_	_
40-27	7656-7659	and	_	_
40-28	7660-7668	timeline	_	_
40-29	7669-7680	follow-back	_	_
40-30	7680-7681	.	_	_

41-1	7682-7685	All	_	_
41-2	7686-7698	participants	_	_
41-3	7699-7703	were	_	_
41-4	7704-7712	required	_	_
41-5	7713-7715	to	_	_
41-6	7716-7723	provide	_	_
41-7	7724-7725	a	_	_
41-8	7726-7734	negative	_	_
41-9	7735-7741	breath	_	_
41-10	7742-7749	alcohol	_	_
41-11	7750-7754	test	_	_
41-12	7755-7758	and	_	_
41-13	7759-7760	a	_	_
41-14	7761-7769	negative	_	_
41-15	7770-7775	urine	_	_
41-16	7776-7782	sample	_	_
41-17	7783-7786	for	_	_
41-18	7787-7794	various	_	_
41-19	7795-7800	drugs	_	_
41-20	7801-7803	of	_	_
41-21	7804-7809	abuse	_	_
41-22	7810-7812	on	_	_
41-23	7813-7816	the	_	_
41-24	7817-7820	day	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
41-25	7821-7823	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
41-26	7824-7831	testing	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
41-27	7832-7833	(	_	_
41-28	7833-7842	screening	_	_
41-29	7843-7846	for	_	_
41-30	7847-7850	the	_	_
41-31	7851-7859	presence	_	_
41-32	7860-7862	of	_	_
41-33	7863-7875	amphetamines	_	_
41-34	7875-7876	,	_	_
41-35	7877-7892	benzodiazepines	_	_
41-36	7892-7893	,	_	_
41-37	7894-7906	cannabinoids	_	_
41-38	7906-7907	,	_	_
41-39	7908-7915	cocaine	_	_
41-40	7916-7919	and	_	_
41-41	7920-7927	opiates	_	_
41-42	7927-7928	)	_	_
41-43	7928-7929	.	_	_

42-1	7930-7933	The	_	_
42-2	7934-7952	Mini-International	_	_
42-3	7953-7969	Neuropsychiatric	_	_
42-4	7970-7979	Interview	_	_
42-5	7980-7981	(	_	_
42-6	7981-7985	MINI	_	_
42-7	7985-7986	)	_	_
42-8	7987-7990	was	_	_
42-9	7991-8003	administered	_	_
42-10	8004-8006	to	_	_
42-11	8007-8010	all	_	_
42-12	8011-8023	participants	_	_
42-13	8024-8026	by	_	_
42-14	8027-8028	a	_	_
42-15	8029-8036	trained	_	_
42-16	8037-8049	psychiatrist	_	_
42-17	8050-8052	to	_	_
42-18	8053-8059	screen	_	_
42-19	8060-8063	for	_	_
42-20	8064-8067	the	_	_
42-21	8068-8076	presence	_	_
42-22	8077-8079	of	_	_
42-23	8080-8084	Axis	_	_
42-24	8085-8086	I	_	_
42-25	8087-8098	psychiatric	_	_
42-26	8099-8108	disorders	_	_
42-27	8109-8113	that	_	_
42-28	8114-8118	were	_	_
42-29	8119-8123	part	_	_
42-30	8124-8126	of	_	_
42-31	8127-8130	the	_	_
42-32	8131-8136	study	_	_
42-33	8137-8146	exclusion	_	_
42-34	8147-8155	criteria	_	_
42-35	8155-8156	.	_	_

43-1	8157-8166	Exclusion	_	_
43-2	8167-8175	criteria	_	_
43-3	8176-8184	included	_	_
43-4	8185-8186	1	_	_
43-5	8186-8187	)	_	_
43-6	8188-8195	current	_	_
43-7	8196-8199	use	_	_
43-8	8200-8202	of	_	_
43-9	8203-8210	regular	_	_
43-10	8211-8223	prescription	_	_
43-11	8224-8226	or	_	_
43-12	8227-8243	non-prescription	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale	_
43-13	8244-8254	medication	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale	_
43-14	8255-8259	that	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale	_
43-15	8260-8265	could	_	_
43-16	8266-8269	not	_	_
43-17	8270-8272	be	_	_
43-18	8273-8280	stopped	_	_
43-19	8280-8281	;	_	_
43-20	8282-8283	2	_	_
43-21	8283-8284	)	_	_
43-22	8285-8292	current	_	_
43-23	8293-8300	primary	_	_
43-24	8301-8305	axis	_	_
43-25	8306-8307	I	_	_
43-26	8308-8317	diagnosis	_	_
43-27	8317-8318	,	_	_
43-28	8319-8323	past	_	_
43-29	8324-8331	history	_	_
43-30	8332-8334	of	_	_
43-31	8335-8344	psychosis	_	_
43-32	8345-8346	(	_	_
43-33	8346-8352	unless	_	_
43-34	8353-8365	drug-induced	_	_
43-35	8365-8366	)	_	_
43-36	8366-8367	;	_	_
43-37	8368-8369	3	_	_
43-38	8369-8370	)	_	_
43-39	8371-8378	current	_	_
43-40	8379-8381	or	_	_
43-41	8382-8386	past	_	_
43-42	8387-8394	history	_	_
43-43	8395-8397	of	_	_
43-44	8398-8406	enduring	_	_
43-45	8407-8413	severe	_	_
43-46	8414-8420	mental	_	_
43-47	8421-8428	illness	_	_
43-48	8429-8430	(	_	_
43-49	8430-8433	e.g	_	_
43-50	8433-8434	.	_	_
43-51	8434-8435	,	_	_
43-52	8436-8449	schizophrenia	_	_
43-53	8449-8450	,	_	_
43-54	8451-8458	bipolar	_	_
43-55	8459-8468	affective	_	_
43-56	8469-8477	disorder	_	_
43-57	8477-8478	)	_	_
43-58	8478-8479	;	_	_
43-59	8480-8481	4	_	_
43-60	8481-8482	)	_	_
43-61	8483-8488	other	_	_
43-62	8489-8496	current	_	_
43-63	8497-8499	or	_	_
43-64	8500-8504	past	_	_
43-65	8505-8516	psychiatric	_	_
43-66	8517-8524	history	_	_
43-67	8525-8529	that	_	_
43-68	8529-8530	,	_	_
43-69	8531-8533	in	_	_
43-70	8534-8537	the	_	_
43-71	8538-8545	opinion	_	_
43-72	8546-8548	of	_	_
43-73	8549-8550	a	_	_
43-74	8551-8563	psychiatrist	_	_
43-75	8563-8564	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
43-76	8565-8580	contraindicated	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
43-77	8581-8594	participation	_	_
43-78	8594-8595	;	_	_
43-79	8596-8597	5	_	_
43-80	8597-8598	)	_	_
43-81	8599-8606	history	_	_
43-82	8607-8609	or	_	_
43-83	8610-8618	presence	_	_
43-84	8619-8621	of	_	_
43-85	8622-8623	a	_	_
43-86	8624-8635	significant	_	_
43-87	8636-8648	neurological	_	http://maven.renci.org/NeuroBridge/neurobridge#TheSocialFunctionQuestionnaire
43-88	8649-8658	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-89	8659-8663	that	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-90	8664-8667	may	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-91	8668-8672	have	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-92	8673-8683	influenced	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-93	8684-8687	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-94	8688-8695	outcome	_	http://maven.renci.org/NeuroBridge/neurobridge#CocaineCravingQuestionnaire_BriefVersion
43-95	8696-8698	or	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-96	8699-8707	analysis	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-97	8708-8710	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-98	8711-8714	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-99	8715-8722	results	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-100	8722-8723	;	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-101	8724-8725	6	_	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-102	8725-8726	)	_	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
43-103	8727-8741	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-104	8742-8744	or	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-105	8745-8751	unable	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-106	8752-8754	to	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-107	8755-8758	lie	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-108	8759-8764	still	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-109	8765-8767	in	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-110	8768-8771	the	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
43-111	8772-8775	MRI	_	_
43-112	8776-8783	scanner	_	_
43-113	8784-8787	for	_	_
43-114	8788-8790	up	_	_
43-115	8791-8793	to	_	_
43-116	8794-8796	90	_	_
43-117	8796-8797	 	_	_
43-118	8797-8800	min	_	_
43-119	8801-8804	and	_	_
43-120	8805-8806	7	_	_
43-121	8806-8807	)	_	_
43-122	8808-8816	presence	_	_
43-123	8817-8819	of	_	_
43-124	8820-8821	a	_	_
43-125	8822-8829	cardiac	_	_
43-126	8830-8839	pacemaker	_	_
43-127	8839-8840	,	_	_
43-128	8841-8846	other	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
43-129	8847-8857	electronic	_	_
43-130	8858-8864	device	_	_
43-131	8865-8867	or	_	_
43-132	8868-8873	other	_	_
43-133	8874-8877	MRI	_	_
43-134	8878-8894	contraindication	_	_
43-135	8894-8895	,	_	_
43-136	8896-8905	including	_	_
43-137	8906-8915	pregnancy	_	_
43-138	8915-8916	,	_	_
43-139	8917-8919	as	_	_
43-140	8920-8928	assessed	_	_
43-141	8929-8931	by	_	_
43-142	8932-8933	a	_	_
43-143	8934-8942	standard	_	_
43-144	8943-8950	pre-MRI	_	_
43-145	8951-8964	questionnaire	_	_
43-146	8964-8965	.	_	_

44-1	8966-8975	Secondary	_	_
44-2	8976-8978	or	_	_
44-3	8979-8987	lifetime	_	_
44-4	8988-8995	history	_	_
44-5	8996-8998	of	_	_
44-6	8999-9009	depression	_	_
44-7	9010-9012	or	_	_
44-8	9013-9020	anxiety	_	_
44-9	9021-9024	was	_	_
44-10	9025-9034	permitted	_	_
44-11	9035-9037	in	_	_
44-12	9038-9042	both	_	_
44-13	9043-9046	the	_	_
44-14	9047-9050	ADD	_	_
44-15	9051-9054	and	_	_
44-16	9055-9058	CON	_	_
44-17	9059-9065	groups	_	_
44-18	9066-9071	since	_	_
44-19	9072-9077	these	_	_
44-20	9078-9081	are	_	_
44-21	9082-9086	very	_	_
44-22	9087-9093	common	_	_
44-23	9094-9105	psychiatric	_	_
44-24	9106-9115	disorders	_	_
44-25	9115-9116	.	_	_

45-1	9117-9120	All	_	_
45-2	9121-9133	participants	_	_
45-3	9134-9142	provided	_	_
45-4	9143-9150	written	_	_
45-5	9151-9159	informed	_	_
45-6	9160-9167	consent	_	_
45-7	9167-9168	.	_	_

46-1	9169-9172	The	_	_
46-2	9173-9178	study	_	_
46-3	9179-9182	was	_	_
46-4	9183-9192	conducted	_	_
46-5	9193-9195	in	_	_
46-6	9196-9206	accordance	_	_
46-7	9207-9211	with	_	_
46-8	9212-9215	the	_	_
46-9	9216-9227	Declaration	_	_
46-10	9228-9230	of	_	_
46-11	9231-9239	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
46-12	9239-9240	.	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised

47-1	9241-9248	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
47-2	9249-9257	approval	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
47-3	9258-9261	was	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
47-4	9262-9270	obtained	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
47-5	9271-9275	from	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
47-6	9276-9280	West	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
47-7	9281-9287	London	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
47-8	9288-9291	and	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
47-9	9292-9296	Gene	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#BerlinQuestionnaire
47-10	9297-9304	Therapy	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	_
47-11	9305-9313	Advisory	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest	http://maven.renci.org/NeuroBridge/neurobridge#orderedPointingTest
47-12	9314-9323	Committee	_	_
47-13	9324-9332	National	_	_
47-14	9333-9341	Research	_	_
47-15	9342-9348	Ethics	_	_
47-16	9349-9356	Service	_	_
47-17	9357-9366	Committee	_	_
47-18	9367-9368	(	_	_
47-19	9368-9370	11	_	_
47-20	9370-9371	/	_	_
47-21	9371-9376	H0707	_	_
47-22	9376-9377	/	_	_
47-23	9377-9378	9	_	_
47-24	9378-9379	)	_	_
47-25	9380-9383	and	_	_
47-26	9384-9392	relevant	_	_
47-27	9393-9401	research	_	_
47-28	9402-9412	governance	_	_
47-29	9413-9416	and	_	_
47-30	9417-9428	Participant	_	_
47-31	9429-9443	Identification	_	_
47-32	9444-9450	Centre	_	_
47-33	9451-9452	(	_	_
47-34	9452-9455	PIC	_	_
47-35	9455-9456	)	_	_
47-36	9457-9466	approvals	_	_
47-37	9467-9475	obtained	_	_
47-38	9475-9476	.	_	_

48-1	9477-9485	Monetary	_	_
48-2	9486-9495	incentive	_	_
48-3	9496-9501	delay	_	_
48-4	9502-9506	task	_	_
48-5	9507-9508	(	_	_
48-6	9508-9511	MID	_	_
48-7	9511-9512	)	_	_
48-8	9513-9515	We	_	_
48-9	9516-9520	used	_	_
48-10	9521-9522	a	_	_
48-11	9523-9524	“	_	_
48-12	9524-9532	monetary	_	_
48-13	9533-9542	incentive	_	_
48-14	9543-9548	delay	_	_
48-15	9549-9553	task	_	_
48-16	9553-9554	”	_	_
48-17	9555-9556	(	_	_
48-18	9556-9559	MID	_	_
48-19	9559-9560	)	_	_
48-20	9560-9561	,	_	_
48-21	9562-9567	which	_	_
48-22	9568-9571	was	_	_
48-23	9572-9577	based	_	_
48-24	9578-9580	on	_	_
48-25	9581-9585	that	_	_
48-26	9586-9596	originally	_	_
48-27	9597-9605	employed	_	_
48-28	9606-9608	by	_	_
48-29	9609-9616	Knutson	_	_
48-30	9616-9617	,	_	_
48-31	9618-9621	and	_	_
48-32	9622-9627	which	_	_
48-33	9628-9630	we	_	_
48-34	9631-9635	have	_	_
48-35	9636-9640	used	_	_
48-36	9641-9643	to	_	_
48-37	9644-9651	already	_	_
48-38	9652-9659	publish	_	_
48-39	9660-9664	data	_	_
48-40	9665-9669	from	_	_
48-41	9670-9673	the	_	_
48-42	9674-9679	ICCAM	_	_
48-43	9680-9688	platform	_	_
48-44	9688-9689	.	_	_

49-1	9690-9692	At	_	_
49-2	9693-9696	the	_	_
49-3	9697-9706	beginning	_	_
49-4	9707-9709	of	_	_
49-5	9710-9714	each	_	_
49-6	9715-9720	trial	_	_
49-7	9720-9721	,	_	_
49-8	9722-9734	participants	_	_
49-9	9735-9741	viewed	_	_
49-10	9742-9745	one	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-11	9746-9748	of	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
49-12	9749-9754	three	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
49-13	9755-9762	symbols	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-14	9763-9764	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
49-15	9764-9765	a	_	_
49-16	9766-9769	cue	_	_
49-17	9769-9770	)	_	_
49-18	9771-9775	that	_	_
49-19	9776-9785	indicated	_	_
49-20	9786-9789	the	_	_
49-21	9790-9799	potential	_	_
49-22	9800-9802	to	_	_
49-23	9803-9807	gain	_	_
49-24	9808-9813	fifty	_	_
49-25	9814-9819	pence	_	_
49-26	9820-9821	(	_	_
49-27	9821-9827	square	_	_
49-28	9828-9838	containing	_	_
49-29	9839-9841	an	_	_
49-30	9842-9851	ascending	_	_
49-31	9852-9857	arrow	_	_
49-32	9857-9858	)	_	_
49-33	9858-9859	,	_	_
49-34	9860-9864	lose	_	_
49-35	9865-9870	fifty	_	_
49-36	9871-9876	pence	_	_
49-37	9877-9878	(	_	_
49-38	9878-9884	square	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
49-39	9885-9895	containing	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
49-40	9896-9897	a	_	_
49-41	9898-9908	descending	_	_
49-42	9909-9914	arrow	_	_
49-43	9914-9915	)	_	_
49-44	9916-9918	or	_	_
49-45	9919-9929	experience	_	_
49-46	9930-9932	no	_	_
49-47	9933-9942	financial	_	_
49-48	9943-9950	outcome	_	_
49-49	9951-9952	(	_	_
49-50	9952-9958	square	_	_
49-51	9959-9969	containing	_	_
49-52	9970-9971	a	_	_
49-53	9972-9982	horizontal	_	_
49-54	9983-9987	line	_	_
49-55	9988-9989	-	_	_
49-56	9990-9994	here	_	_
49-57	9995-10003	referred	_	_
49-58	10004-10006	to	_	_
49-59	10007-10009	as	_	_
49-60	10010-10011	a	_	_
49-61	10012-10019	neutral	_	_
49-62	10020-10025	trial	_	_
49-63	10025-10026	)	_	_
49-64	10026-10027	.	_	_

50-1	10028-10032	Each	_	_
50-2	10033-10036	cue	_	_
50-3	10037-10040	was	_	_
50-4	10041-10050	presented	_	_
50-5	10051-10054	for	_	_
50-6	10055-10058	one	_	_
50-7	10059-10065	second	_	_
50-8	10065-10066	,	_	_
50-9	10067-10071	with	_	_
50-10	10072-10073	a	_	_
50-11	10074-10082	variable	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
50-12	10083-10091	duration	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
50-13	10092-10093	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
50-14	10093-10094	2	_	_
50-15	10094-10095	–	_	_
50-16	10095-10096	4	_	_
50-17	10096-10097	 	_	_
50-18	10097-10098	s	_	_
50-19	10098-10099	)	_	_
50-20	10100-10103	for	_	_
50-21	10104-10107	the	_	_
50-22	10108-10118	subsequent	_	_
50-23	10119-10131	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	_
50-24	10132-10138	period	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
50-25	10138-10139	.	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging

51-1	10140-10149	Following	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
51-2	10150-10153	the	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
51-3	10154-10166	anticipation	_	_
51-4	10167-10173	period	_	_
51-5	10173-10174	,	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
51-6	10175-10187	participants	_	_
51-7	10188-10192	made	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
51-8	10193-10194	a	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
51-9	10195-10201	button	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
51-10	10202-10207	press	_	http://maven.renci.org/NeuroBridge/neurobridge#ImagingModality
51-11	10208-10216	response	_	_
51-12	10217-10221	upon	_	_
51-13	10222-10225	the	_	_
51-14	10226-10238	presentation	_	_
51-15	10239-10241	of	_	_
51-16	10242-10243	a	_	_
51-17	10244-10250	visual	_	_
51-18	10251-10257	target	_	_
51-19	10258-10259	(	_	_
51-20	10259-10263	star	_	_
51-21	10264-10271	located	_	_
51-22	10272-10278	within	_	_
51-23	10279-10280	a	_	_
51-24	10281-10287	circle	_	_
51-25	10287-10288	)	_	_
51-26	10288-10289	.	_	_

52-1	10290-10299	Following	_	_
52-2	10300-10305	their	_	_
52-3	10306-10314	response	_	_
52-4	10315-10317	to	_	_
52-5	10318-10321	the	_	_
52-6	10322-10328	visual	_	_
52-7	10329-10335	target	_	_
52-8	10335-10336	,	_	_
52-9	10337-10349	participants	_	_
52-10	10350-10358	received	_	_
52-11	10359-10367	feedback	_	_
52-12	10368-10369	(	_	_
52-13	10369-10372	1.5	_	_
52-14	10372-10373	 	_	_
52-15	10373-10374	s	_	_
52-16	10374-10375	)	_	_
52-17	10376-10378	as	_	_
52-18	10379-10381	to	_	_
52-19	10382-10389	whether	_	_
52-20	10390-10394	they	_	_
52-21	10395-10399	were	_	_
52-22	10400-10410	successful	_	_
52-23	10411-10412	(	_	_
52-24	10412-10413	“	_	_
52-25	10413-10416	Hit	_	_
52-26	10416-10417	”	_	_
52-27	10417-10418	)	_	_
52-28	10419-10421	or	_	_
52-29	10422-10434	unsuccessful	_	_
52-30	10435-10436	(	_	_
52-31	10436-10437	“	_	_
52-32	10437-10441	Miss	_	_
52-33	10441-10442	”	_	_
52-34	10442-10443	)	_	_
52-35	10444-10446	on	_	_
52-36	10447-10451	that	_	_
52-37	10452-10457	trial	_	_
52-38	10458-10461	and	_	_
52-39	10462-10465	saw	_	_
52-40	10466-10467	a	_	_
52-41	10468-10475	running	_	_
52-42	10476-10481	total	_	_
52-43	10482-10484	of	_	_
52-44	10485-10490	their	_	_
52-45	10491-10499	winnings	_	_
52-46	10500-10502	up	_	_
52-47	10503-10505	to	_	_
52-48	10506-10510	that	_	_
52-49	10511-10516	point	_	_
52-50	10517-10519	in	_	_
52-51	10520-10523	the	_	_
52-52	10524-10528	task	_	_
52-53	10528-10529	.	_	_

53-1	10530-10539	Following	_	_
53-2	10540-10548	feedback	_	_
53-3	10548-10549	,	_	_
53-4	10550-10555	there	_	_
53-5	10556-10559	was	_	_
53-6	10560-10562	an	_	_
53-7	10563-10566	end	_	_
53-8	10567-10575	fixation	_	_
53-9	10576-10582	period	_	_
53-10	10583-10584	(	_	_
53-11	10584-10585	3	_	_
53-12	10585-10586	–	_	_
53-13	10586-10587	5	_	_
53-14	10587-10588	 	_	_
53-15	10588-10589	s	_	_
53-16	10589-10590	)	_	_
53-17	10591-10597	before	_	_
53-18	10598-10601	the	_	_
53-19	10602-10614	commencement	_	_
53-20	10615-10617	of	_	_
53-21	10618-10621	the	_	_
53-22	10622-10626	next	_	_
53-23	10627-10632	trial	_	_
53-24	10632-10633	.	_	_

54-1	10634-10641	Because	_	_
54-2	10642-10645	the	_	_
54-3	10646-10653	primary	_	_
54-4	10654-10663	objective	_	_
54-5	10664-10666	of	_	_
54-6	10667-10672	ICCAM	_	_
54-7	10673-10676	was	_	_
54-8	10677-10679	to	_	_
54-9	10680-10687	examine	_	_
54-10	10688-10691	the	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
54-11	10692-10698	neural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
54-12	10699-10709	correlates	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
54-13	10710-10712	of	_	_
54-14	10713-10719	reward	_	_
54-15	10720-10732	anticipation	_	_
54-16	10732-10733	,	_	_
54-17	10734-10736	we	_	_
54-18	10737-10742	chose	_	_
54-19	10743-10745	to	_	_
54-20	10746-10749	use	_	_
54-21	10750-10751	a	_	_
54-22	10752-10759	smaller	_	_
54-23	10760-10766	number	_	_
54-24	10767-10769	of	_	_
54-25	10770-10774	loss	_	_
54-26	10775-10781	trials	_	_
54-27	10782-10784	in	_	_
54-28	10785-10790	order	_	_
54-29	10791-10793	to	_	_
54-30	10794-10801	amplify	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
54-31	10802-10805	the	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
54-32	10806-10815	incentive	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
54-33	10816-10824	salience	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
54-34	10825-10827	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
54-35	10828-10831	the	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
54-36	10832-10836	gain	_	_
54-37	10837-10843	trials	_	_
54-38	10844-10850	during	_	_
54-39	10851-10854	the	_	_
54-40	10855-10859	task	_	_
54-41	10859-10860	.	_	_

55-1	10861-10873	Consequently	_	_
55-2	10873-10874	,	_	_
55-3	10875-10880	there	_	_
55-4	10881-10884	was	_	_
55-5	10885-10886	a	_	_
55-6	10887-10892	total	_	_
55-7	10893-10895	of	_	_
55-8	10896-10898	18	_	_
55-9	10899-10903	gain	_	_
55-10	10903-10904	,	_	_
55-11	10905-10906	6	_	_
55-12	10907-10911	lose	_	_
55-13	10912-10915	and	_	_
55-14	10916-10918	18	_	_
55-15	10919-10926	neutral	_	_
55-16	10927-10933	trials	_	_
55-17	10934-10936	on	_	_
55-18	10937-10941	each	_	_
55-19	10942-10945	run	_	_
55-20	10946-10948	of	_	_
55-21	10949-10952	the	_	_
55-22	10953-10957	task	_	_
55-23	10957-10958	.	_	_

56-1	10959-10962	The	_	_
56-2	10963-10966	MID	_	_
56-3	10967-10971	task	_	_
56-4	10972-10975	was	_	_
56-5	10976-10984	tailored	_	_
56-6	10985-10987	to	_	_
56-7	10988-10993	adapt	_	_
56-8	10994-10996	to	_	_
56-9	10997-11000	the	_	_
56-10	11001-11007	visual	_	_
56-11	11008-11014	target	_	_
56-12	11015-11023	reaction	_	_
56-13	11024-11028	time	_	_
56-14	11029-11031	of	_	_
56-15	11032-11036	each	_	_
56-16	11037-11048	participant	_	_
56-17	11049-11051	by	_	_
56-18	11052-11057	using	_	_
56-19	11058-11059	a	_	_
56-20	11060-11069	staircase	_	_
56-21	11070-11079	algorithm	_	_
56-22	11079-11080	,	_	_
56-23	11081-11085	such	_	_
56-24	11086-11090	that	_	_
56-25	11091-11094	the	_	_
56-26	11095-11107	presentation	_	_
56-27	11108-11110	of	_	_
56-28	11111-11114	the	_	_
56-29	11115-11121	visual	_	_
56-30	11122-11128	target	_	_
56-31	11129-11135	became	_	_
56-32	11136-11143	shorter	_	_
56-33	11144-11146	as	_	_
56-34	11147-11158	performance	_	_
56-35	11159-11167	improved	_	_
56-36	11168-11174	during	_	_
56-37	11175-11178	the	_	_
56-38	11179-11189	experiment	_	_
56-39	11189-11190	.	_	_

57-1	11191-11195	This	_	_
57-2	11196-11203	enabled	_	_
57-3	11204-11206	us	_	_
57-4	11207-11209	to	_	_
57-5	11210-11213	set	_	_
57-6	11214-11215	a	_	_
57-7	11216-11221	limit	_	_
57-8	11222-11224	on	_	_
57-9	11225-11228	the	_	_
57-10	11229-11236	success	_	_
57-11	11237-11241	rate	_	_
57-12	11242-11244	of	_	_
57-13	11245-11249	each	_	_
57-14	11250-11261	participant	_	_
57-15	11262-11263	(	_	_
57-16	11263-11264	∼	_	_
57-17	11264-11267	66%	_	_
57-18	11267-11268	)	_	_
57-19	11268-11269	,	_	_
57-20	11270-11275	which	_	_
57-21	11276-11288	additionally	_	_
57-22	11289-11295	served	_	_
57-23	11296-11298	to	_	_
57-24	11299-11310	incentivize	_	_
57-25	11311-11323	participants	_	_
57-26	11324-11326	to	_	_
57-27	11327-11333	engage	_	_
57-28	11334-11336	in	_	_
57-29	11337-11340	the	_	_
57-30	11341-11345	task	_	_
57-31	11345-11346	.	_	_

58-1	11347-11359	Participants	_	_
58-2	11360-11364	were	_	_
58-3	11365-11375	instructed	_	_
58-4	11376-11378	to	_	_
58-5	11379-11387	maximize	_	_
58-6	11388-11393	their	_	_
58-7	11394-11402	winnings	_	_
58-8	11403-11406	and	_	_
58-9	11407-11411	were	_	_
58-10	11412-11416	told	_	_
58-11	11417-11421	they	_	_
58-12	11422-11427	would	_	_
58-13	11428-11435	receive	_	_
58-14	11436-11440	them	_	_
58-15	11441-11443	at	_	_
58-16	11444-11447	the	_	_
58-17	11448-11451	end	_	_
58-18	11452-11454	of	_	_
58-19	11455-11458	the	_	_
58-20	11459-11464	study	_	_
58-21	11464-11465	.	_	_

59-1	11466-11475	Dependent	_	_
59-2	11476-11484	measures	_	_
59-3	11485-11489	were	_	_
59-4	11490-11498	accuracy	_	_
59-5	11499-11500	(	_	_
59-6	11500-11510	percentage	_	_
59-7	11510-11511	)	_	_
59-8	11512-11515	and	_	_
59-9	11516-11520	mean	_	_
59-10	11521-11529	reaction	_	_
59-11	11530-11534	time	_	_
59-12	11535-11536	(	_	_
59-13	11536-11548	milliseconds	_	_
59-14	11548-11549	)	_	_
59-15	11550-11552	to	_	_
59-16	11553-11556	the	_	_
59-17	11557-11563	visual	_	_
59-18	11564-11570	target	_	_
59-19	11571-11573	on	_	_
59-20	11574-11578	each	_	_
59-21	11579-11581	of	_	_
59-22	11582-11585	the	_	_
59-23	11586-11590	gain	_	_
59-24	11590-11591	,	_	_
59-25	11592-11596	lose	_	_
59-26	11597-11600	and	_	_
59-27	11601-11608	neutral	_	_
59-28	11609-11615	trials	_	_
59-29	11615-11616	,	_	_
59-30	11617-11620	and	_	_
59-31	11621-11624	the	_	_
59-32	11625-11631	amount	_	_
59-33	11632-11635	won	_	_
59-34	11636-11637	(	_	_
59-35	11637-11638	£	_	_
59-36	11638-11639	)	_	_
59-37	11640-11642	on	_	_
59-38	11643-11646	the	_	_
59-39	11647-11651	task	_	_
59-40	11651-11652	.	_	_

60-1	11653-11665	Participants	_	_
60-2	11666-11675	completed	_	_
60-3	11676-11679	two	_	_
60-4	11680-11684	runs	_	_
60-5	11685-11687	of	_	_
60-6	11688-11691	the	_	_
60-7	11692-11696	task	_	_
60-8	11697-11698	(	_	_
60-9	11698-11701	432	_	_
60-10	11701-11702	 	_	_
60-11	11702-11703	s	_	_
60-12	11704-11708	each	_	_
60-13	11708-11709	)	_	_
60-14	11710-11716	during	_	_
60-15	11717-11725	scanning	_	_
60-16	11725-11726	.	_	_

61-1	11727-11730	The	_	_
61-2	11731-11735	task	_	_
61-3	11736-11739	was	_	_
61-4	11740-11750	programmed	_	_
61-5	11751-11756	using	_	_
61-6	11757-11764	E-Prime	_	_
61-7	11765-11772	version	_	_
61-8	11773-11776	2.0	_	_
61-9	11777-11778	(	_	_
61-10	11778-11788	Psychology	_	_
61-11	11789-11797	Software	_	_
61-12	11798-11803	Tools	_	_
61-13	11803-11804	,	_	_
61-14	11805-11815	Pittsburgh	_	_
61-15	11815-11816	,	_	_
61-16	11817-11820	USA	_	_
61-17	11820-11821	)	_	_
61-18	11821-11822	.	_	_

62-1	11823-11833	Statistics	_	_
62-2	11834-11839	Group	_	_
62-3	11840-11852	demographics	_	_
62-4	11853-11857	were	_	_
62-5	11858-11866	compared	_	_
62-6	11867-11872	using	_	_
62-7	11873-11879	simple	_	_
62-8	11880-11891	independent	_	_
62-9	11892-11899	samples	_	_
62-10	11900-11906	t-test	_	_
62-11	11907-11915	analyses	_	_
62-12	11915-11916	.	_	_

63-1	11917-11920	For	_	_
63-2	11921-11929	analyses	_	_
63-3	11930-11939	conducted	_	_
63-4	11940-11942	on	_	_
63-5	11943-11946	MID	_	_
63-6	11947-11958	performance	_	_
63-7	11958-11959	,	_	_
63-8	11960-11963	two	_	_
63-9	11964-11965	(	_	_
63-10	11965-11970	Group	_	_
63-11	11970-11971	:	_	_
63-12	11972-11975	CON	_	_
63-13	11976-11978	vs	_	_
63-14	11978-11979	.	_	_

64-1	11980-11983	ADD	_	_
64-2	11983-11984	)	_	_
64-3	11985-11987	by	_	_
64-4	11988-11991	two	_	_
64-5	11992-11993	(	_	_
64-6	11993-12002	Condition	_	_
64-7	12002-12003	:	_	_
64-8	12004-12008	Gain	_	_
64-9	12009-12011	vs	_	_
64-10	12011-12012	.	_	_

65-1	12013-12020	Neutral	_	_
65-2	12020-12021	)	_	_
65-3	12022-12030	analyses	_	_
65-4	12031-12033	of	_	_
65-5	12034-12042	variance	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
65-6	12043-12047	were	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
65-7	12048-12057	conducted	_	_
65-8	12057-12058	.	_	_

66-1	12059-12062	The	_	_
66-2	12063-12066	CON	_	_
66-3	12067-12070	and	_	_
66-4	12071-12074	ADD	_	_
66-5	12075-12081	groups	_	_
66-6	12082-12086	were	_	_
66-7	12087-12091	also	_	_
66-8	12092-12100	compared	_	_
66-9	12101-12103	on	_	_
66-10	12104-12107	the	_	_
66-11	12108-12112	lose	_	_
66-12	12113-12121	accuracy	_	_
66-13	12122-12125	and	_	_
66-14	12126-12130	lose	_	_
66-15	12131-12139	reaction	_	_
66-16	12140-12144	time	_	_
66-17	12145-12156	performance	_	_
66-18	12157-12165	measures	_	_
66-19	12165-12166	,	_	_
66-20	12167-12169	as	_	_
66-21	12170-12174	well	_	_
66-22	12175-12177	as	_	_
66-23	12178-12181	the	_	_
66-24	12182-12188	amount	_	_
66-25	12189-12191	of	_	_
66-26	12192-12197	money	_	_
66-27	12198-12201	won	_	_
66-28	12202-12203	(	_	_
66-29	12203-12204	£	_	_
66-30	12204-12205	)	_	_
66-31	12205-12206	,	_	_
66-32	12207-12212	using	_	_
66-33	12213-12221	analyses	_	_
66-34	12222-12224	of	_	_
66-35	12225-12233	variance	_	_
66-36	12233-12234	.	_	_

67-1	12235-12240	These	_	_
67-2	12241-12249	analyses	_	_
67-3	12250-12254	were	_	_
67-4	12255-12264	conducted	_	_
67-5	12265-12276	controlling	_	_
67-6	12277-12280	for	_	_
67-7	12281-12286	study	_	_
67-8	12287-12291	site	_	_
67-9	12291-12292	.	_	_

68-1	12293-12296	For	_	_
68-2	12297-12300	the	_	_
68-3	12301-12306	graph	_	_
68-4	12307-12315	measures	_	_
68-5	12316-12317	(	_	_
68-6	12317-12320	see	_	_
68-7	12321-12326	below	_	_
68-8	12326-12327	)	_	_
68-9	12328-12330	we	_	_
68-10	12331-12340	conducted	_	_
68-11	12341-12344	two	_	_
68-12	12345-12346	(	_	_
68-13	12346-12351	Group	_	_
68-14	12351-12352	:	_	_
68-15	12353-12356	CON	_	_
68-16	12357-12359	vs	_	_
68-17	12359-12360	.	_	_

69-1	12361-12364	ADD	_	_
69-2	12364-12365	)	_	_
69-3	12366-12368	by	_	_
69-4	12369-12373	five	_	_
69-5	12374-12375	(	_	_
69-6	12375-12376	1	_	_
69-7	12376-12377	 	_	_
69-8	12377-12378	⩽	_	_
69-9	12378-12379	 	_	_
69-10	12379-12380	K	_	_
69-11	12380-12381	 	_	_
69-12	12381-12382	⩽	_	_
69-13	12382-12383	 	_	_
69-14	12383-12384	5	_	_
69-15	12384-12385	)	_	_
69-16	12386-12394	analyses	_	_
69-17	12395-12397	of	_	_
69-18	12398-12406	variance	_	_
69-19	12406-12407	,	_	_
69-20	12408-12413	while	_	_
69-21	12414-12418	also	_	_
69-22	12419-12430	controlling	_	_
69-23	12431-12434	for	_	_
69-24	12435-12440	study	_	_
69-25	12441-12445	site	_	_
69-26	12445-12446	.	_	_

70-1	12447-12450	All	_	_
70-2	12451-12456	these	_	_
70-3	12457-12465	analyses	_	_
70-4	12466-12470	were	_	_
70-5	12471-12480	conducted	_	_
70-6	12481-12486	using	_	_
70-7	12487-12498	permutation	_	_
70-8	12499-12506	testing	_	_
70-9	12507-12508	(	_	_
70-10	12508-12512	5000	_	_
70-11	12513-12523	iterations	_	_
70-12	12523-12524	)	_	_
70-13	12525-12527	in	_	_
70-14	12528-12531	the	_	_
70-15	12532-12533	R	_	_
70-16	12534-12545	statistical	_	_
70-17	12546-12554	software	_	_
70-18	12555-12562	package	_	_
70-19	12563-12564	(	_	_
70-20	12564-12581	www.R-project.org	_	_
70-21	12581-12582	)	_	_
70-22	12582-12583	.	_	_

71-1	12584-12594	Functional	_	_
71-2	12595-12598	MRI	_	_
71-3	12599-12600	(	_	_
71-4	12600-12604	fMRI	_	_
71-5	12604-12605	)	_	_
71-6	12606-12610	Data	_	_
71-7	12611-12622	acquisition	_	_
71-8	12623-12626	The	_	_
71-9	12627-12632	ICCAM	_	_
71-10	12633-12641	platform	_	_
71-11	12642-12645	was	_	_
71-12	12646-12654	designed	_	_
71-13	12655-12657	to	_	_
71-14	12658-12663	allow	_	_
71-15	12664-12667	the	_	_
71-16	12668-12673	rapid	_	_
71-17	12674-12681	testing	_	_
71-18	12682-12688	across	_	_
71-19	12689-12694	sites	_	_
71-20	12695-12697	of	_	_
71-21	12698-12706	multiple	_	_
71-22	12707-12716	compounds	_	_
71-23	12717-12725	relevant	_	_
71-24	12726-12728	to	_	_
71-25	12729-12738	addiction	_	_
71-26	12739-12748	treatment	_	_
71-27	12748-12749	.	_	_

72-1	12750-12757	Imaging	_	_
72-2	12758-12760	at	_	_
72-3	12761-12769	multiple	_	_
72-4	12770-12775	sites	_	_
72-5	12776-12778	in	_	_
72-6	12779-12787	parallel	_	_
72-7	12788-12790	on	_	_
72-8	12791-12794	the	_	_
72-9	12795-12800	ICCAM	_	_
72-10	12801-12809	platform	_	_
72-11	12810-12821	accelerated	_	_
72-12	12822-12827	study	_	_
72-13	12828-12838	completion	_	_
72-14	12838-12839	,	_	_
72-15	12840-12847	through	_	_
72-16	12848-12851	the	_	_
72-17	12852-12859	sharing	_	_
72-18	12860-12862	of	_	_
72-19	12863-12872	expertise	_	_
72-20	12872-12873	,	_	_
72-21	12874-12888	infrastructure	_	_
72-22	12889-12892	and	_	_
72-23	12893-12901	capacity	_	_
72-24	12901-12902	.	_	_
72-25	12902-12903	 	_	_

73-1	12903-12906	For	_	_
73-2	12907-12908	a	_	_
73-3	12909-12913	more	_	_
73-4	12914-12927	comprehensive	_	_
73-5	12928-12939	description	_	_
73-6	12940-12942	of	_	_
73-7	12943-12947	data	_	_
73-8	12948-12959	acquisition	_	_
73-9	12960-12966	across	_	_
73-10	12967-12970	the	_	_
73-11	12971-12976	three	_	_
73-12	12977-12982	sites	_	_
73-13	12983-12985	on	_	_
73-14	12986-12991	ICCAM	_	_
73-15	12991-12992	,	_	_
73-16	12993-12999	please	_	_
73-17	13000-13003	see	_	_
73-18	13004-13013	McGonigle	_	_
73-19	13014-13016	et	_	_
73-20	13017-13019	al	_	_
73-21	13019-13020	.	_	_

74-1	13021-13028	Briefly	_	_
74-2	13028-13029	,	_	_
74-3	13030-13033	all	_	_
74-4	13034-13041	centres	_	_
74-5	13042-13050	operated	_	_
74-6	13051-13054	MRI	_	_
74-7	13055-13063	machines	_	_
74-8	13064-13068	with	_	_
74-9	13069-13070	a	_	_
74-10	13071-13075	main	_	_
74-11	13076-13084	magnetic	_	_
74-12	13085-13090	field	_	_
74-13	13091-13093	of	_	_
74-14	13094-13095	3	_	_
74-15	13095-13096	 	_	_
74-16	13096-13097	T	_	_
74-17	13098-13099	(	_	_
74-18	13099-13100	T	_	_
74-19	13100-13101	)	_	_
74-20	13101-13102	.	_	_

75-1	13103-13110	Centres	_	_
75-2	13111-13113	in	_	_
75-3	13114-13120	London	_	_
75-4	13121-13124	and	_	_
75-5	13125-13134	Cambridge	_	_
75-6	13135-13143	operated	_	_
75-7	13144-13153	nominally	_	_
75-8	13154-13163	identical	_	_
75-9	13164-13165	3	_	_
75-10	13165-13166	 	_	_
75-11	13166-13167	T	_	_
75-12	13168-13175	Siemens	_	_
75-13	13176-13179	Tim	_	_
75-14	13180-13184	Trio	_	_
75-15	13185-13192	systems	_	_
75-16	13193-13200	running	_	_
75-17	13201-13204	the	_	_
75-18	13205-13210	syngo	_	_
75-19	13211-13213	MR	_	_
75-20	13214-13217	B17	_	_
75-21	13218-13226	software	_	_
75-22	13227-13231	with	_	_
75-23	13232-13233	a	_	_
75-24	13234-13241	Siemens	_	_
75-25	13242-13244	32	_	_
75-26	13245-13252	channel	_	_
75-27	13253-13265	receive-only	_	_
75-28	13266-13278	phased-array	_	_
75-29	13279-13283	head	_	_
75-30	13284-13288	coil	_	_
75-31	13288-13289	.	_	_

76-1	13290-13293	The	_	_
76-2	13294-13304	Manchester	_	_
76-3	13305-13311	centre	_	_
76-4	13312-13320	operated	_	_
76-5	13321-13322	a	_	_
76-6	13323-13324	3	_	_
76-7	13324-13325	 	_	_
76-8	13325-13326	T	_	_
76-9	13327-13334	Philips	_	_
76-10	13335-13342	Achieva	_	_
76-11	13343-13350	running	_	_
76-12	13351-13358	version	_	_
76-13	13359-13366	2.6.3.5	_	_
76-14	13367-13375	software	_	_
76-15	13376-13379	and	_	_
76-16	13380-13382	an	_	_
76-17	13383-13384	8	_	_
76-18	13385-13392	element	_	_
76-19	13393-13398	SENSE	_	_
76-20	13399-13403	head	_	_
76-21	13404-13408	coil	_	_
76-22	13408-13409	.	_	_

77-1	13410-13413	For	_	_
77-2	13414-13424	anatomical	_	_
77-3	13425-13431	images	_	_
77-4	13431-13432	,	_	_
77-5	13433-13436	160	_	_
77-6	13437-13452	high-resolution	_	_
77-7	13453-13455	T1	_	_
77-8	13455-13456	-	_	_
77-9	13456-13464	weighted	_	_
77-10	13465-13473	anatomic	_	_
77-11	13474-13480	MPRAGE	_	_
77-12	13481-13486	axial	_	_
77-13	13487-13493	images	_	_
77-14	13494-13495	(	_	_
77-15	13495-13498	FOV	_	_
77-16	13499-13502	256	_	_
77-17	13502-13503	 	_	_
77-18	13503-13505	mm	_	_
77-19	13505-13506	,	_	_
77-20	13507-13516	thickness	_	_
77-21	13517-13520	1.0	_	_
77-22	13520-13521	 	_	_
77-23	13521-13523	mm	_	_
77-24	13523-13524	,	_	_
77-25	13525-13530	voxel	_	_
77-26	13531-13535	size	_	_
77-27	13536-13539	1.0	_	_
77-28	13539-13540	 	_	_
77-29	13540-13541	×	_	_
77-30	13541-13542	 	_	_
77-31	13542-13545	1.0	_	_
77-32	13545-13546	 	_	_
77-33	13546-13547	×	_	_
77-34	13547-13548	 	_	_
77-35	13548-13551	1.0	_	_
77-36	13551-13552	)	_	_
77-37	13553-13557	were	_	_
77-38	13558-13566	acquired	_	_
77-39	13567-13568	(	_	_
77-40	13568-13573	total	_	_
77-41	13574-13582	duration	_	_
77-42	13583-13586	303	_	_
77-43	13586-13587	 	_	_
77-44	13587-13588	s	_	_
77-45	13588-13589	)	_	_
77-46	13589-13590	.	_	_

78-1	13591-13601	Functional	_	_
78-2	13602-13606	data	_	_
78-3	13607-13611	were	_	_
78-4	13612-13620	acquired	_	_
78-5	13621-13626	using	_	_
78-6	13627-13628	a	_	_
78-7	13629-13631	T2	_	_
78-8	13631-13632	*	_	_
78-9	13633-13641	weighted	_	_
78-10	13642-13653	echo-planar	_	_
78-11	13654-13661	imaging	_	_
78-12	13662-13670	sequence	_	_
78-13	13671-13681	collecting	_	_
78-14	13682-13684	36	_	_
78-15	13685-13699	non-contiguous	_	_
78-16	13700-13701	(	_	_
78-17	13701-13703	0%	_	_
78-18	13704-13707	gap	_	_
78-19	13707-13708	)	_	_
78-20	13709-13712	3.0	_	_
78-21	13712-13713	 	_	_
78-22	13713-13715	mm	_	_
78-23	13716-13721	axial	_	_
78-24	13722-13728	slices	_	_
78-25	13729-13737	covering	_	_
78-26	13738-13741	the	_	_
78-27	13742-13748	entire	_	_
78-28	13749-13754	brain	_	_
78-29	13755-13756	(	_	_
78-30	13756-13758	TE	_	_
78-31	13758-13759	 	_	_
78-32	13759-13760	=	_	_
78-33	13760-13761	 	_	_
78-34	13761-13763	31	_	_
78-35	13763-13764	 	_	_
78-36	13764-13766	ms	_	_
78-37	13766-13767	,	_	_
78-38	13768-13770	TR	_	_
78-39	13770-13771	 	_	_
78-40	13771-13772	=	_	_
78-41	13772-13773	 	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
78-42	13773-13777	2000	_	_
78-43	13777-13778	 	_	_
78-44	13778-13780	ms	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
78-45	13780-13781	,	_	_
78-46	13782-13785	FOV	_	_
78-47	13786-13789	225	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
78-48	13789-13790	 	_	_
78-49	13790-13792	mm	_	_
78-50	13792-13793	,	_	_
78-51	13794-13796	64	_	_
78-52	13796-13797	 	_	_
78-53	13797-13798	×	_	_
78-54	13798-13799	 	_	_
78-55	13799-13801	64	_	_
78-56	13801-13802	 	_	_
78-57	13802-13804	mm	_	_
78-58	13805-13811	matrix	_	_
78-59	13812-13816	size	_	_
78-60	13817-13819	in	_	_
78-61	13820-13827	Fourier	_	_
78-62	13828-13833	space	_	_
78-63	13833-13834	)	_	_
78-64	13834-13835	.	_	_

79-1	13836-13840	Each	_	_
79-2	13841-13844	run	_	_
79-3	13845-13847	of	_	_
79-4	13848-13851	the	_	_
79-5	13852-13855	MID	_	_
79-6	13856-13860	task	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-7	13861-13869	produced	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-8	13870-13871	a	_	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-9	13872-13877	total	_	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-10	13878-13880	of	_	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-11	13881-13884	216	_	_
79-12	13885-13892	volumes	_	_
79-13	13893-13895	of	_	_
79-14	13896-13906	functional	_	_
79-15	13907-13910	MRI	_	_
79-16	13911-13915	data	_	_
79-17	13915-13916	.	_	_
79-18	13917-13921	fMRI	_	_
79-19	13922-13926	Data	_	_
79-20	13927-13935	analyses	_	_
79-21	13936-13940	Data	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
79-22	13941-13955	pre-processing	_	_
79-23	13956-13959	and	_	_
79-24	13960-13971	statistical	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
79-25	13972-13980	analysis	_	_
79-26	13981-13985	were	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
79-27	13986-13995	conducted	_	_
79-28	13996-14001	using	_	_
79-29	14002-14006	FEAT	_	_
79-30	14007-14008	(	_	_
79-31	14008-14012	fMRI	_	_
79-32	14013-14019	Expert	_	_
79-33	14020-14028	Analysis	_	_
79-34	14029-14033	Tool	_	_
79-35	14033-14034	)	_	_
79-36	14035-14039	from	_	_
79-37	14040-14043	the	_	_
79-38	14044-14049	FMRIB	_	_
79-39	14050-14058	Software	_	_
79-40	14059-14066	Library	_	_
79-41	14067-14068	(	_	_
79-42	14068-14086	www.fmrib.ox.ac.uk	_	_
79-43	14086-14087	/	_	_
79-44	14087-14090	fsl	_	_
79-45	14090-14091	)	_	_
79-46	14091-14092	.	_	_

